Based on the collected results once-daily rivaroxaban 20 mg was chosen to be assessed in nonvalvular atrial fibrillation in ROCKET-AF (Rivaroxaban-once daily, oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) study [7] and approved for the reduction in the risk of stroke and systematic embolism in patients suffering from nonvalvular atrial fibrillation by the European Medicines Agency in September 2011 [8] and by the Food and Drug Administration (FDA) in November 2011 [9]. Here, F10 is linked to stroke disorder.